6 completed, 3 unknown, 1 active not recruiting. 10 Phase 1, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 10 | Completed 6, Unknown 3, Active not recruiting 1 |
| Phase 2 | 4 | Unknown 2, Active not recruiting 1, Completed 1 |
Follow Candidiasis, Vulvovaginal: new trials by email Literature Review of Candidiasis, Vulvovaginal trials Research Report on Candidiasis, Vulvovaginal
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy, Safety, and Dose-response of a Live Biotherapeutic Product in Women With Acute Vaginal Infection BGY-1601-VT, PLACEBO - Bacterial Vaginosis, Vulvovaginal Candidiasis | Phase 1 / Phase 2 | Unknown | NEXBIOME THERAPEUTICS | 165 | 2024-07-08 | 2024-06-12 |
| Safety and Tolerability Studies of CanProFem-AK, Vaginal Suppositories in Healthy Volunteers CanProFem-AK - Candidosis Vaginal | Phase 1 | Completed | Industrial Microbiology LLP | 20 | 2024-06-01 | 2024-08-02 |
| Assessing the Safety, Immune Response, and Early Efficacy of a Candida Vaccine in Women With Recurrent Vulvovaginal Candidiasis: A Randomized Controlled Study Vaccine - Recurrent Vulvovaginal Candidiasis | Phase 1 / Phase 2 | Active not recruiting | LimmaTech Biologics AG | 251 | 2023-12-06 | 2026-03-04 |
| Pharmacokinetic Study in Healthy Lactating Women Exposed to Ibrexafungerp Ibrexafungerp - Vulvovaginal Candidiasis, Candida Infection | Phase 1 | Completed | Scynexis, Inc. | 5 | 2023-07-12 | 2025-08-08 |
| Patients With Vulvovaginal Candidiasis EPP-AF Gel 1%, EPP-AF Gel 2%, Clotrimazole - Vulvovaginal Candidiasis | Phase 1 / Phase 2 | Unknown | University of Sao Paulo | 90 | 2018-01-30 | 2018-10-19 |
| Study Evaluating the Optimal Dosage for Equivalence Between Lcr Regenerans® Capsules and Tablets (Lactobacillus Rhamnosus Lcr35®) on the Vaginal Flora Colonisation Lcr Regenerans® vaginal capsules, Lcr Regenerans® vaginal tablet - Candidiasis, Vulvovaginal | Phase 1 | Completed | Biose | 34 | 2015-07-01 | 2018-02-05 |
| Safety, Tolerability, Immunogenicity and Efficacy of NDV-3A Vaccine in Preventing Recurrent Vulvovaginal Candidiasis NDV-3A, NDV-3, Placebo - Vulvovaginal Candidiasis | Phase 1 / Phase 2 | Completed | NovaDigm Therapeutics, Inc. | 188 | 2013-07-01 | 2018-07-18 |
| Evaluation of Intravaginal Gel and Ovule Formulations of TOL-463 TOL-463 Vaginal ovule, TOL-463 Vaginal gel - Vaginal Infection | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 26 | 2013-04-01 | 2014-05-16 |
| Safety and Immunogenicity Study of a Virosomal Vaccine Against Recurrent Vulvovaginal Candida Infection PEV7C1, PEV7C9, PEV7B2 - Recurrent Vulvovaginal Candidiasis | Phase 1 | Completed | Pevion Biotech Ltd | 48 | 2010-03-01 | 2012-12-24 |
| Use of Oral Probiotics as an Adjunctive Therapy to Fluconazole in the Treatment of Yeast Vaginitis Probiotics (Natural product), Probiotics (L. rhamnosus GR-1 and L. reuteri RC-14) - Vaginal Candidiasis | Phase 1 | Unknown | Faith Mediplex | 100 | 2007-05-01 | 2007-05-30 |
Candidiasis (2) · Mycoses (2) · Torulopsis (2) · Vaginitis (2) · Vaginosis, Bacterial (2) · Candidiasis, Oral (1)
Bacterial Infections and Mycoses (10) · Female Urogenital Diseases (10) · Female Urogenital Diseases and Pregnancy Complications (10) · Genital Diseases (10) · Genital Diseases, Female (10) · Infections (10) · Urogenital Diseases (10) · Vaginal Diseases (10) · Vulvar Diseases (10) · Vulvitis (10) · Vulvovaginitis (10) · Candidiasis (8) · Mycoses (8) · Vaginitis (8) · Bacterial Infections (2)
Biological Products (1) · Clotrimazole (1) · Probiotics (1) · Vaccines (1) · ibrexafungerp (1)
Biose (1) · Faith Mediplex (1) · Industrial Microbiology LLP (1) · LimmaTech Biologics AG (1) · NEXBIOME THERAPEUTICS (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · NovaDigm Therapeutics, Inc. (1) · Pevion Biotech Ltd (1) · Scynexis, Inc. (1) · University of Sao Paulo (1)
United States (3) · Belgium (1) · Brazil (1) · France (1) · Kazakhstan (1) · Nigeria (1) · Poland (1) · Switzerland (1)
Giuseppe Pantaleo, Prof (1) · John P. Hennessey, Jr., Ph.D. (1) · Rolf Pokorny, MD, MSc (1)
2014 (1), 2023 (1)